Theranos documentary backlash
AI & tech · Heat 2.4 / 10 · 5 shows · 1h 4m airtime
A Theranos documentary aired in October 2026 and returned Elizabeth Holmes to the spotlight, with some viewers reading her more sympathetically. The pushback notes a Stanford chemical engineering professor told Holmes he did not believe the technology worked, and WIRED has published an Adam Rogers piece reckoning with its own early coverage. Reporting has widened the frame: more than 60 diagnostics companies have sold for over $100 million since Theranos, GeneWeave raised $25 million and sold for $425 million, and Roche's MRSA test won FDA authorization in 2019. Balwani was sentenced to 12 years and 11 months; Holmes got 10 years, cut from 11 years and three months. Her partner Billy Evans now runs a startup developing blood, saliva and…
How 5 podcasts covered it
- TBPN, 2026-10-20 (0:02 to 4:15)
Argues Holmes was a bad founder apart from fraud
Reacts to the documentary's reception and argues Holmes was a bad founder apart from the fraud, noting more than 60 diagnostics companies since Theranos have sold for over $100 million and that device makers cannot claim a product works before FDA authorization.
New angle: More than 60 diagnostics companies since Theranos have sold for over $100 million. - TBPN, 2026-10-20 (4:15 to 6:33)
Picks apart the spoiler and the back-end deal
Picks a documentary spoiler apart: Billy Evans took points on the film's back end and backed out after production. Speculates about whether the couple is legally married and whether routing profits through him dodges Holmes's restitution, which she has put in the hundreds of millions. - TBPN, 2026-10-20 (6:33 to 8:48)
Pitches what a redemption arc would require
Extends the documentary backlash into a hypothetical: what a Holmes redemption arc would require. One host recounts a call with Billy about Theranos 2.0 and pitches a specific diagnostic; the hosts want market maps and a 2027 thesis, not vision. Stays inside the reaction to the film. - TBPN, 2026-10-20 (8:50 to 10:02)
Adds GeneWeave as the counterexample
Uses GeneWeave as the counterexample to Holmes: a real diagnostics box, built by Diego Rey, that raised $25 million and sold for $425 million, with Roche later winning FDA authorization for its MRSA test in 2019.
New angle: GeneWeave raised $25 million and sold for $425 million; Roche's MRSA test won FDA authorization in 2019. - TBPN, 2026-10-20 (10:02 to 11:22)
Corrects the sentencing comparison
Corrects the documentary's implication that Balwani got off lighter than Holmes, laying out the actual sentences, and lands on the fact that neither founder sold secondary shares at an $11 billion valuation.
New angle: Balwani was sentenced to 12 years and 11 months; Holmes got 10 years, cut from 11 years and three months. - This Week in Startups, 2026-10-22 (50:16 to 1:02:37)
Asks the VCs about backing a new Holmes
Hypothetical segment: the VCs are asked whether they would invest in a new Holmes company. Lessin and Fielding say they would take a quick secondary flip, Doherty would take the meeting but not invest. Calacanis sketches a halfway-house timeline and a Trump-era sentence cut; the substance stays inside the documentary backlash discussion. - Science Weekly, 2026-10-22 (1:50 to 3:14)
Frames the documentary as reason to revisit Holmes
Opens the episode by introducing Theranos and Elizabeth Holmes - the few-drops-of-blood promise, the Stanford origin, the fraud and jail - and frames the new documentary as the reason to revisit her.
New angle: A new documentary has returned Elizabeth Holmes to the spotlight. - Science Weekly, 2026-10-22 (3:00 to 5:50)
Recaps the valuation, the deal and the failures
Recaps the Theranos saga behind the documentary: the Stanford dropout, the $9 billion valuation, the Walgreens deal, the Edison machine's failures and the fraud prosecution. Background retelling that stays inside the story already on the record. - Science Weekly, 2026-10-22 (5:50 to 7:29)
Explains the borrowed Silicon Valley playbook
Explains how Holmes borrowed Silicon Valley's faking-it ethos - the black turtleneck from Steve Jobs, the trade-secrets shield - and notes no health care investors backed Theranos. Background on the fraud, not new reporting on the documentary. - Science Weekly, 2026-10-22 (7:42 to 9:28)
Cites the professor who doubted the technology
Turns to the science-versus-startup-culture question and puts on the record a detail from the earlier Theranos documentary: a Stanford chemical engineering professor told Holmes to her face that he did not believe the technology worked and that she had not shown him evidence.
New angle: A Stanford chemical engineering professor told Holmes he did not believe the technology worked. - Science Weekly, 2026-10-22 (9:24 to 12:23)
Adds the partner's blood-testing startup
Pulls the Holmes story out of the documentary and into the present: her partner Billy Evans now runs a startup developing blood, saliva and urine testing, which the guest calls bizarre given her sentence barred her from blood testing for years.
New angle: Elizabeth Holmes's partner Billy Evans runs a startup developing blood, saliva and urine testing. - Uncanny Valley | WIRED, 2026-10-22 (1:43 to 13:27)
Adds WIRED's reckoning with its Theranos coverage
Drummond recounts the NDA-shrouded pitch for Nathan Fielder's Theranos film and her interview with him, then turns to WIRED's own reckoning: Adam Rogers' piece on the magazine's early praise of Theranos and why today's WIRED would not have run that 2014 interview.
New angle: WIRED published an Adam Rogers piece reckoning with its own early Theranos coverage. - Hard Fork, 2026-10-23 (36:22 to 38:43)
Reports the Bad Blood sellout and new printing
Carreyrou, back on the show, describes the documentary's viral reception: Bad Blood is sold out in New York bookstores and Knopf has printed another 10,000 copies. He also says the film is built around whether Holmes knew she and Evans would profit from the A24 deal.
New angle: Knopf printed another 10,000 copies of Bad Blood after the documentary's release. - Hard Fork, 2026-10-23 (39:22 to 41:24)
Cites the one-drop promise and the Minilab mix-up
Carreyrou answers a listener question on the strongest fraud evidence: Holmes promised hundreds of tests from one drop while the Edison did 12, all voided. He adds that the device Holmes unpacks in the film is the unfinished Minilab, not the Edison.
New angle: The device Holmes unpacks in the documentary is the unfinished Minilab, not the Edison used on patients. - Hard Fork, 2026-10-23 (41:24 to 46:21)
Tells the whistleblower backstory the film leaves out
Brings in Carreyrou to tell the whistleblower backstory the documentary leaves out: how Rosendorff pointed him to Tyler Shultz, Shultz's failed warnings to Holmes and his grandfather, the ambush at the Shultz house, and Holmes's appeal to Murdoch to kill the story.
New angle: Holmes went to Murdoch's News Corp office to ask him to kill the Journal story; he had put in $125 million. - Hard Fork, 2026-10-23 (46:21 to 48:30)
Answers whether Balwani was behind it all
Carreyrou answers a listener's devil's-advocate question about whether Balwani was behind it all. He points to thousands of texts the government obtained from 2009 to 2016 showing the pair ran Theranos as a couple, and notes Holmes held roughly 90 percent voting control as CEO and chairman.
New angle: The government obtained thousands of Holmes-Balwani texts from 2009 to 2016 showing they ran Theranos as a couple. - Hard Fork, 2026-10-23 (48:30 to 54:40)
Dates the fraud to the fall 2013 Walgreens launch
Carreyrou, the reporter who broke Theranos, reads the documentary's 'miscommunication' defense and the Abbott and Costello scene as calculated. He dates the full-fledged fraud to fall 2013, when Theranos went live in Walgreens on hacked, double-diluted Siemens machines.
New angle: Theranos ran Walgreens tests in fall 2013 on modified Siemens machines with pre-diluted finger-stick samples, double-diluting them.